within Pharmacolibrary.Drugs.N_NervousSystem.N01B_AnestheticsLocal.N01BB10_Levobupivacaine;

model Levobupivacaine
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_2C(
    weight = 70,
    F = 1,
    Cl = 8.166666666666666e-06,
    adminDuration = 600,
    adminMass = 40 / 1000000,
    adminCount = 1,
    Vd = 0.044,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    Vdp = 0.021,
    k12 = 4.666666666666667e-06,
    k21 = 4.666666666666667e-06);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Levobupivacaine</td></tr><tr><td>ATC code:</td><td>N01BB10</td></tr><td>route:</td><td>intravenous</td></tr>
    <tr><td>compartments:</td><td>2</td></tr>
    <tr><td>dosage:</td><td>40</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>44</td><td>L</td></tr>
    <tr><td>clearance:</td><td>0.49</td><td>L/min</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Levobupivacaine is a long-acting local anesthetic that is the S(-)-enantiomer of bupivacaine. It is used for regional anesthesia including epidural, caudal, and peripheral nerve block, as well as infiltration anesthesia in surgical, obstetric, and pain management procedures. It is approved and widely used today due to a lower risk of cardiotoxicity than racemic bupivacaine.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported in healthy adult volunteers after intravenous administration.</p><h4>References</h4><ol><li><p>Olofsen, E, et al., &amp; Dahan, A (2008). Population pharmacokinetic-pharmacodynamic modeling of epidural anesthesia. <i>Anesthesiology</i> 109(4) 664–674. DOI:<a href=\"https://doi.org/10.1097/01.anes.0000334302.50559.c9\">10.1097/01.anes.0000334302.50559.c9</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/18813046/\">https://pubmed.ncbi.nlm.nih.gov/18813046</a></p></li><li><p>Mossetti, V, et al., &amp; Ivani, G (2012). Local anesthetis and adjuvants in pediatric regional anesthesia. <i>Current drug targets</i> 13(7) 952–960. DOI:<a href=\"https://doi.org/10.2174/138945012800675713\">10.2174/138945012800675713</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/22512395/\">https://pubmed.ncbi.nlm.nih.gov/22512395</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.N.N01BB10 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Levobupivacaine;
